DP 001

Drug Profile

DP 001

Alternative Names: 2MD; DP-001; PF-00217763

Latest Information Update: 21 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Wisconsin-Madison
  • Developer Deltanoid Pharmaceuticals
  • Class Osteoporosis therapies; Small molecules; Vitamin D analogues
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Secondary hyperparathyroidism
  • No development reported Postmenopausal osteoporosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Aug 2015 Phase II development for Secondary hyperparathyroidism is ongoing in the USA
  • 08 Aug 2015 No recent reports of development identified - Phase-II for Postmenopausal osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top